SPATA17

Across TCGA pan-cancer cohorts, SPATA17 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated SPATA17 data layer compared with 6 for mutation status.

The strongest signal is observed in rectum adenocarcinoma (READ), where higher SPATA17 RNA is associated with better overall survival. In most high-consensus cancer types, elevated SPATA17 expression acts as an unfavorable survival marker, although some lineages such as READ and BRCA show a favorable association.

READ, LIHC, and LGG are the cancer types where SPATA17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
READ	OS	Median	All	0.977	0.841	<.001	76	view →
LIHC	OS	Tertile	All	0.688	0.845	<.001	65	view →
LGG	DFS	Median	All	0.628	0.848	<.001	54	view →
CHOL	DFS	Median	All	0.244	0.700	.003	25	view →
BRCA	DFS	Tertile	III,IV	0.840	0.685	.008	19	view →
ACC	OS	Median	IV	0.307	0.734	.003	18	view →
BLCA	DFS	Tertile	III,IV	0.078	0.344	.008	17	view →
OV	DFS	Median	III,IV	0.571	0.493	.012	16	view →
SCLC	DFS	Median	IV	0.137	0.559	.008	15	view →
PAAD	DFS	Tertile	All	0.397	0.183	.008	15	view →
ESCA	DFS	Median	II,III,IV	0.460	0.276	.024	15	view →
LAML	DFS	Tertile	All	0.447	0.739	.016	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

SPATA17–READ (OS)

Open the READ breakdown →